Maximillian A Rogers

age ~43

from Cambridge, MA

Get Report
Also known as:
  • Max A Rogers
  • Maximillia Rogers
  • Rogers Maxa
Related to:
Connected to:

Maximillian Rogers Phones & Addresses

  • Cambridge, MA
  • 46 Melrose St APT 1, Boston, MA 02116
  • Hanover, NH
  • Seattle, WA
  • Goleta, CA
  • South Cle Elum, WA
  • White River Junction, VT

Work

  • Company:
    Harvard medical school
    Jan 2019
  • Position:
    Research associate

Education

  • School / High School:
    Harvard Medical School
    2012 to 2018
  • Specialities:
    Medicine

Skills

Molecular Biology • Cell Biology • Biochemistry • Western Blotting • Cell Culture • Immunohistochemistry • Clinical Research • Data Analysis • Protein Purification • Biology • Medical Research • Scientific Writing • Cardiovascular Disease • Cancer • Endocrinology • Validation • Pcr • Genetics • Mass Spectrometry • Fluorescence Microscopy • Protein Expression • Gel Electrophoresis • Neuroscience • Polymerase Chain Reaction • Flow Cytometry • Teaching • Metabolism • Crispr • Gene Editing • Exosome Characterization • Aav • Lifesciences • Research • Pharmaceutical Industry • Science • Life Sciences

Languages

English • Spanish

Industries

Research

Resumes

Maximillian Rogers Photo 1

Research Scientist At Bwh And Kowa Company Ltd

view source
Location:
Boston, MA
Industry:
Research
Work:
Harvard Medical School
Research Associate
Brigham and Women's Hospital
Research Scientist
Harvard Medical School Sep 2012 - Dec 2018
Research Fellow In Medicine
Dartmouth College Apr 2011 - Sep 2012
Nih Kirschstein-Nrsa Fellow
Kowa Company and Bwh Cics Apr 2011 - Sep 2012
Research Scientist at Bwh and Kowa Company Ltd
Education:
Harvard Medical School 2012 - 2018
Geisel School of Medicine at Dartmouth 2005 - 2011
Doctorates, Doctor of Philosophy, Molecular Biology, Biochemistry, Philosophy University of Washington 2000 - 2004
Bachelors, Bachelor of Arts, Bachelor of Science
Skills:
Molecular Biology
Cell Biology
Biochemistry
Western Blotting
Cell Culture
Immunohistochemistry
Clinical Research
Data Analysis
Protein Purification
Biology
Medical Research
Scientific Writing
Cardiovascular Disease
Cancer
Endocrinology
Validation
Pcr
Genetics
Mass Spectrometry
Fluorescence Microscopy
Protein Expression
Gel Electrophoresis
Neuroscience
Polymerase Chain Reaction
Flow Cytometry
Teaching
Metabolism
Crispr
Gene Editing
Exosome Characterization
Aav
Lifesciences
Research
Pharmaceutical Industry
Science
Life Sciences
Languages:
English
Spanish

Us Patents

  • Method For Selectively Inhibiting Acat1 In The Treatment Of Alzheimer's Disease

    view source
  • US Patent:
    20140044757, Feb 13, 2014
  • Filed:
    Sep 11, 2013
  • Appl. No.:
    14/023952
  • Inventors:
    Catherine C.Y. Chang - Etna NH, US
    Yohei Shibuya - West Lebanon NH, US
    Elena Bryleva - Lebanon NH, US
    Stephanie Murphy - West Lebanon NH, US
    Maximillian A. Rogers - White River Junction VT, US
  • Assignee:
    Trustees of Dartmouth College - Hanover NH
  • International Classification:
    A61K 31/713
    A61K 31/44
    A61K 31/255
    A61K 9/00
  • US Classification:
    424400, 514 44 A, 514346, 514517
  • Abstract:
    The present invention features methods for stimulating clearance of amyloid beta in microglia, decreasing cognitive decline associated with amyloid pathology, and treating Alzheimer's disease by selectively inhibiting the expression or activity of Acyl-CoA:Cholesterol Acyltransferase 1, but not Acyl-CoA:Cholesterol Acyltransferase 2.

  • Methods And Compositions Relating To Inhibiting Cardiovascular Calcification Via Annexin A1

    view source
  • US Patent:
    20210353721, Nov 18, 2021
  • Filed:
    Aug 7, 2019
  • Appl. No.:
    17/265238
  • Inventors:
    - Boston MA, US
    Maximillian ROGERS - Boston MA, US
    Masanori AIKAWA - Chestnut Hill MA, US
  • Assignee:
    THE BRIGHAM AND WOMEN'S HOSPITAL, INC. - Boston MA
  • International Classification:
    A61K 38/48
    A61K 31/513
    A61K 31/198
    C07K 16/18
    C12N 15/113
  • Abstract:
    The technology described herein is directed methods of treating an extracellular vesicle (EV)-associated disease or vascular calcification in subject by administration of an agent that reduces the levels or activity of Annexin A1 (ANXA1).

  • Modulation Of Pcsk9 And Ldlr Through Drp1 Inhibition

    view source
  • US Patent:
    20190209603, Jul 11, 2019
  • Filed:
    Sep 12, 2017
  • Appl. No.:
    16/333460
  • Inventors:
    - Boston MA, US
    Maximillian ROGERS - Boston MA, US
    Masanori AIKAWA - Chestnut Hill MA, US
  • Assignee:
    THE BRIGHAM AND WOMEN'S HOSPITAL, INC. - Boston MA
  • International Classification:
    A61K 31/7105
    A61P 3/06
    C12N 15/115
    C12N 15/113
  • Abstract:
    Provided herein are methods for reducing levels of blood cholesterol, low-density lipoprotein (LDL), and/or the treatment of diseases associated with high cholesterol, hyperlipidemia, dyslipidemia, or high levels of low-density lipoprotein (LDL), wherein the methods comprise administering a DRP1 inhibitor to a subject in need thereof. In certain embodiments, the subject is selected for treatment as described herein when the subject exhibits intolerance to conventional statin therapy. Also contemplated herein are the use of DRP1 inhibitors in the treatment of cancer and inflammatory disease.

  • Methods For Treating Niemann-Pick Type C Disease

    view source
  • US Patent:
    20140220114, Aug 7, 2014
  • Filed:
    Jul 24, 2012
  • Appl. No.:
    14/235482
  • Inventors:
    Ta-Yuan Chang - Etna NH, US
    Catherine C.Y. Chang - Etna NH, US
    Maximillian A. Rogers - White River Junction VT, US
  • Assignee:
    TRUSTEES OF DARTMOUTH COLLEGE - Hanover NH
  • International Classification:
    C12N 15/113
    A61K 31/713
  • US Classification:
    424450, 514 44 A
  • Abstract:
    The present invention includes methods for treating Niemann-Pick Type C disease through administration of inhibitors of acyl-coenzyme A:cholesterol acyltransferase 1 (ACAT1). ACAT inhibitors are used to treat symptoms of Niemann-Pick Type C disease and prolong survival of patients with the disease, either alone or in combination with other treatments.

Googleplus

Maximillian Rogers Photo 2

Maximillian Rogers

Get Report for Maximillian A Rogers from Cambridge, MA, age ~43
Control profile